Phenelzine API Manufacturers

Looking for Phenelzine API 51-71-8?

Description:

Here you will find a list of producers, manufacturers and distributors of Phenelzine. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Phenelzine 

Synonyms:

Alazine , Fenelzina , Monofen , Nardil , Phenelzin , Phenelzinum  

Cas Number:

51-71-8 

DrugBank number:

DB00780 

Unique Ingredient Identifier:

O408N561GF

Phenelzine is a type of MAO inhibitors

MAO inhibitors, also known as monoamine oxidase inhibitors, are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) widely used in the treatment of various medical conditions. These medications work by inhibiting the activity of the enzyme monoamine oxidase, which plays a crucial role in breaking down neurotransmitters such as serotonin, dopamine, and norepinephrine.

The primary therapeutic application of MAO inhibitors is in the management of depression. By blocking the action of monoamine oxidase, these drugs increase the levels of neurotransmitters in the brain, leading to improved mood and alleviation of depressive symptoms. MAO inhibitors have shown efficacy in treating both major depressive disorder and treatment-resistant depression.

Moreover, MAO inhibitors have also demonstrated utility in the treatment of anxiety disorders and certain types of Parkinson's disease. In anxiety disorders, these medications help regulate neurotransmitter imbalances that contribute to anxiety symptoms. In Parkinson's disease, MAO inhibitors inhibit the breakdown of dopamine, a neurotransmitter crucial for motor control, leading to improved movement and symptom control.

Although MAO inhibitors offer therapeutic benefits, they require careful monitoring and dietary restrictions due to potential interactions with certain foods and other medications. Consumption of foods rich in tyramine, such as aged cheese, cured meats, and fermented products, can lead to a hypertensive crisis when combined with MAO inhibitors. Additionally, MAO inhibitors can interact adversely with certain medications, such as selective serotonin reuptake inhibitors (SSRIs), leading to serotonin syndrome.

In conclusion, MAO inhibitors are a valuable subcategory of pharmaceutical APIs used in the treatment of depression, anxiety disorders, and Parkinson's disease. While they provide therapeutic benefits, it is essential to follow dietary restrictions and closely monitor medication interactions to ensure patient safety.

Phenelzine (MAO inhibitors), classified under Central Nervous System Agents

Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.

CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.

The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.

Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.

• Siegfried from Germany, product country of origin Unknown
• Procos from Italy, product country of origin Italy

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.